Aegis-RSI about Home Insurance

4 (1 votes)

Carrington Laboratories, Inc. (Nasdaq: CARN) reported today that GelVac(TM), a dry powder nasal delivery formulation for vaccines, showed each antigen stabilization and high immunogenic impact in preclinical models. Furthermore, ongoing studies of GelVac(TM) formulations incorporating influenza antigens exhibited the potential for long-term stability through storage at space temperature.

In a presentation entitled “A Stable Dry Powder Vaccine Formulation (GelVac(TM)) for Nasal Delivery” at the 2006 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition October 29- November 2, 2006 in San Antonio, Texas, Babu M. Medi, PhD, Pharmaceutical Scientist at DelSite Biotechnologies, Carrington’s wholly-owed subsidiary, described preparation and characterization of GelVac(TM) stable dry powder vaccine formulations for nasal delivery of vaccines using various drying strategies.

The information showed the antigens had been protected from activity loss during the dry powder formulation procedure, keeping their potency. Additionally, the GelSite(R) polymer, the crucial ingredient of GelVac(TM) powder formulations, exhibited a distinct antigen stabilization effect in addition to conferring in situ gelling properties, both of which serve to increase the uptake of active antigens inside the nasal cavity.

Equally important, the preservative-free dry powdered formulations incorporating influenza antigens had been shown to be stable for over 18 months in the course of storage at ambient space temperature (nonetheless ongoing). They had been also very immunogenic, eliciting robust immune responses in animals right after nasal delivery.

GelSite(R) polymer offers an in situ gelling property for optimal nasal delivery. Upon hydration by nasal fluid, the GelVac(TM) formulation adjustments from dry powder particles to wet gel particles, resulting in the formation of a gel that adheres to nasal mucus, thus maximizing antigen exposure through prolonged nasal residence time and sustained antigen release.

An abstract of this presentation might be located on DelSite’s site at http://www.delsite.com/newfiles/sci_pubs.html.

About GelSite(R) Polymer

GelSite polymer can be a novel, naturally derived high-molecular-weight polygalacturonic acid. It possesses distinct chemical and functional properties proprietary towards the Company, which includes in situ gelling. It really is manufactured under cGMP as a highly pure dry substance.

About GelVac(TM)

GelVac(TM) can be a proprietary nasal powder vaccine delivery technique according to the GelSite(R) polymer, the main functional ingredient that confers its exclusive in situ gelling property. The GelVac(TM) method combines the positive aspects of dry powder formulations and nasal immunization, including space temperature stability, prolonged shelf life, and no want for preservatives, and induction of systemic and mucosal immune responses.

About DelSite

DelSite Biotechnologies, Inc. is actually a drug delivery and biotechnology business established to supply the pharmaceutical and biotechnology industries with novel delivery solutions for vaccines and therapeutic agents. DelSite is a wholly owned subsidiary of Carrington Laboratories, Inc. and was formed according to discoveries at Carrington.

About Carrington

Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer items organization at present utilizing naturally- occurring complex carbohydrates to manufacture and marketplace products for mucositis, radiation dermatitis, wound and oral care, and also to manufacture and market place the nutraceutical raw material Manapol(R) and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer merchandise and manufactures top quality merchandise for other organizations. Manufacturing operations comply with cGMP standards. Carrington’s technology is protected by much more than 130 patents in 26 countries. Pick goods carry the CE mark, recognized worldwide. For a lot more info, go to http://www.carringtonlabs.com.

Specific statements in this release regarding Carrington may be forward- searching. Actual events is going to be dependent upon quite a few aspects and risks which includes, but not restricted to: subsequent adjustments in plans by the Company’s management; delays or issues in formulation, manufacturing, distribution, production and/or launch of new finished goods; modifications within the regulatory process; changes in industry trends; plus a number of other elements and risks described from time to time inside the Company’s filings using the Securities & Exchange Commission, including the Form 10-Q, filed August 14, 2006.

Carrington Laboratories, Inc.
http://www.carringtonlabs.com

View drug information on Carrington patch.